Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non‐small‐cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two gene...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Med
Prif Awduron: Pataer, Apar, Shao, Ruping, Correa, Arlene M., Behrens, Carmen, Roth, Jack A., Vaporciyan, Ara A., Wistuba, Ignacio I., Swisher, Stephen G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Clinical Cancer Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010873/
https://ncbi.nlm.nih.gov/pubmed/29673125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1505
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg